Collegium Pharmaceutical (COLL) Common Equity (2014 - 2026)

Collegium Pharmaceutical's Common Equity history runs 13 years deep, the most recent figure standing at $312.4 million for Q1 2026.

• In Q1 2026, Common Equity rose 33.27% year-over-year to $312.4 million; the TTM figure through Mar 2026 stood at $312.4 million (up 33.27% YoY), while the FY2025 annual figure was $301.7 million, up 31.83% from the prior year.
• Common Equity was $312.4 million for Q1 2026 at Collegium Pharmaceutical, up from $301.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $312.4 million in Q1 2026 to a low of $178.9 million in Q3 2023.
• Historically, Common Equity has averaged $223.4 million across 5 years, with a median of $216.6 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Common Equity decreased 21.91% in 2022, then soared 33.27% in 2026.
• A 5-year view of Common Equity shows it stood at $194.8 million in 2022, then climbed by 0.3% to $195.4 million in 2023, then climbed by 17.1% to $228.8 million in 2024, then jumped by 31.83% to $301.7 million in 2025, then grew by 3.56% to $312.4 million in 2026.
• The last three Common Equity figures came in at $312.4 million (Q1 2026), $301.7 million (Q4 2025), and $274.8 million (Q3 2025), per Business Quant data.